Zydus Lifesciences launches Olaparib

13 Mar 2024 Evaluate

Zydus Lifesciences has launched Olaparib, a PARP inhibitor, under the brand name IBYRA in India. The drug will target specific genetic mutations prevalent in certain types of cancers, paving the way for more tailored and effective treatment approach. 

Out of 14 lakh newly diagnosed cancer patients in India, nearly 2.75 lakh patients are diagnosed with breast, ovarian, prostrate and pancreatic cancers as per Globocan 2022 data. Amongst these patients, those who are diagnosed as HRD positive or with BRACA mutation need to be administered this PARP inhibitor which can delay the progression of the disease. IBYRA is a next gen targeted therapy for HRD positive and BRACA positive cancer patients. To help identify the right patients and facilitate access, Zydus Lifesciences has collaborated with MedGenome for comprehensive HRD testing. This alongwith a year-long treatment of IBYRA has been capped at Rs 3 lakh as compared to the cost of around Rs 72 lakh by the innovator. 

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.


Zydus Lifesciences Share Price

900.25 5.25 (0.59%)
13-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1729.80
Dr. Reddys Lab 1190.35
Cipla 1447.60
Zydus Lifesciences 900.25
Lupin 2176.80
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×